- Home
- PMVP vs PRLD Comparison
PMVP vs PRLD Comparison
Compare PMVP & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- PRLD
- Stock Information
- Founded
- PMVP 2013
- PRLD 2016
- Country
- PMVP United States
- PRLD United States
- Employees
- PMVP N/A
- PRLD N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- PMVP Health Care
- PRLD Health Care
- Exchange
- PMVP Nasdaq
- PRLD Nasdaq
- Market Cap
- PMVP 55.1M
- PRLD 48.6M
- IPO Year
- PMVP 2020
- PRLD 2020
- Fundamental
- Price
- PMVP $1.31
- PRLD $0.88
- Analyst Decision
- PMVP Strong Buy
- PRLD Strong Buy
- Analyst Count
- PMVP 1
- PRLD 2
- Target Price
- PMVP $5.00
- PRLD $4.50
- AVG Volume (30 Days)
- PMVP 265.0K
- PRLD 208.9K
- Earning Date
- PMVP 08-07-2025
- PRLD 08-11-2025
- Dividend Yield
- PMVP N/A
- PRLD N/A
- EPS Growth
- PMVP N/A
- PRLD N/A
- EPS
- PMVP N/A
- PRLD N/A
- Revenue
- PMVP N/A
- PRLD $7,000,000.00
- Revenue This Year
- PMVP N/A
- PRLD N/A
- Revenue Next Year
- PMVP N/A
- PRLD N/A
- P/E Ratio
- PMVP N/A
- PRLD N/A
- Revenue Growth
- PMVP N/A
- PRLD N/A
- 52 Week Low
- PMVP $0.81
- PRLD $0.61
- 52 Week High
- PMVP $1.82
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- PMVP 68.35
- PRLD 48.56
- Support Level
- PMVP $0.96
- PRLD $0.78
- Resistance Level
- PMVP $1.36
- PRLD $0.88
- Average True Range (ATR)
- PMVP 0.09
- PRLD 0.07
- MACD
- PMVP 0.02
- PRLD -0.00
- Stochastic Oscillator
- PMVP 79.80
- PRLD 50.06
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.